Insights
Insights From Our Experts
Articles
Precision Medicine and Predictive Action Drive Measurable Impact for Patients
The Institute for Precision Medicine defines “Precision Medicine” as the “medical approach that proposes to prevent and treat disease based upon a person’s unique genetic makeup and their lifestyle habits. Precision medicine, the ability to accurately…
Webinar: Improve Hub Performance and Patient Outcomes
The use of health data technologies and analytics in the life sciences industry continues to evolve, but many manufacturers are still crawling around in the dark. With limited in-person patient and provider-rep interactions, hubs that lack…
How to Scale Your Learning & Development Department: Ask The Expert
For years, Learning and Development teams have been asked to “do more with less.” When budgets tightened, teams would get more creative allocating their resources and time. But today – in the midst of changing market…
Webinar: CMS Final Rule on Cost-Sharing Assistance
The CMS final rule on drug reimbursement addresses how co-pay coupons and vouchers are being exempted from deductibles by PBMs. The rule seems to ensure that the full value of manufacturers’ coupon and voucher programs accrue…
Change Is Happening in the EU: What Pharma Companies Need to Know About the European Union’s New Pharmaceutical Strategy
For the first time, the European Union is undergoing a major overhaul of its pharmaceutical industry with the new Pharmaceutical Strategy for Europe, which was launched in late 2020. Through this strategy, the European Union (EU) is making…
News Alert: MCIT Implementation Delayed
On Friday, March 12, the Centers for Medicare and Medicaid Services (CMS) issued an Interim Final Rule with Comment (IFC) delaying the effective date of the Medicare Coverage of Innovative Technologies (MCIT) initiative from March 15…
BLOG: Not So Rare… The True Impact of Rare Diseases
Posted by
Dr. Richard Stefanacci on March 15, 20213/15/21
Rare disease treatments seem to be everywhere today. This is true despite the fact that to be considered a rare disease, fewer than 200,000 patients are affected — and for ultra-rare, fewer than 7,000 patients are affected. This definition was created by Congress in the Orphan Drug Act of 1983. Rare diseases became known as orphan…
Webinar: Drug Pricing and Reporting Regulatory Updates Part 2
In Part 2 of our Drug Pricing and Reporting Regulatory Updates webinar, EVERSANA revenue experts take a look at the Final Rule, which was released by the Centers for Medicare and Medicaid Services in December 2020.…
Webinar: Drug Pricing and Reporting Regulatory Updates Part 1
Pharmaceutical companies in the U.S. are navigating President Biden’s new administration and legislative changes that are affecting pricing and regulatory actions. One of these changes includes the regulatory freeze ordered for actions made in the final two months of…
Watch Now: PharmaVOICE Panel on Next Gen Patient Services Models
The Future of Data-Driven Patient Support Is Now The use of health data technologies and analytics in the life sciences industry continues to evolve, but many manufacturers are still crawling around in the dark. With limited…